Allergy Immunopathophysiology
Allergic diseases (atopic dermatitis, allergic rhinitis, asthma, food allergy; affecting 30–40% of adults globally) are driven by type 2 immune responses: Th2 CD4+ T cells produce IL-4/IL-13 (triggering B cell IgE class-switch recombination via AID/AICDA), IL-5 (eosinophil survival/activation), and IL-33/TSLP (epithelial alarmins from barrier disruption). IgE binds high-affinity FcεRI receptors on mast cells/basophils; antigen cross-linking triggers degranulation (preformed: histamine, tryptase, serotonin; newly synthesised: PGD2, LTC4/D4/E4 cysteinyl leukotrienes). Chronic allergen exposure perpetuates Th2 dominance over Th1 and T-regulatory (Treg; Foxp3+; IL-10/TGF-β secreting) subsets, impairing oral/mucosal tolerance. Eosinophil tissue infiltration (RANTES/CCL5, eotaxin/CCL11 chemokines via NF-κB) drives chronic inflammation and structural remodelling (subepithelial fibrosis, goblet cell hyperplasia).
Spirulina Mechanisms in Allergy Modulation
IgE Class-Switch Suppression via IL-4/IL-13 Reduction
Spirulina phycocyanin inhibits NF-κB and STAT6 in Th2 cells and antigen-presenting cells, reducing IL-4 production by 25–40% and IL-13 by 20–35% under allergen stimulation. Reduced IL-4/IL-13 signalling through IL-4Rα/γc impairs STAT6-driven AID expression in B cells, suppressing IgE class-switch recombination by 25–40% and reducing allergen-specific IgE titres (−20–35% total IgE in atopic models). Phycocyanin also reduces IL-33 and TSLP release from airway epithelial cells under allergen challenge, dampening the upstream alarmin cascade that initiates Th2 polarisation of naïve T cells.
Mast Cell Stabilisation and Histamine Release Inhibition
Spirulina polyphenols and phycocyanin stabilise mast cell membranes through: (1) MAPK/PKC pathway suppression, reducing calcium influx-dependent degranulation; (2) inhibition of Syk kinase phosphorylation downstream of FcεRI cross-linking (−30–40% Syk activity); (3) direct ROS scavenging preventing lipid peroxidation-driven membrane destabilisation. Histamine release −30–45% in IgE-sensitised mast cells challenged with antigen. Newly synthesised lipid mediators: PGD2 −25–40% (COX-2 inhibition), cysteinyl leukotrienes (LTC4/D4/E4) −20–35% (5-LOX suppression). Clinical correlates: reduced nasal itch, sneezing, and urticaria frequency.
Th2→Treg Polarisation Restoration
Spirulina β-glucan binds Dectin-1 on dendritic cells, promoting tolerogenic DC differentiation and IL-10/TGF-β secretion over IL-12/IL-4 (Th1/Th2-polarising cytokines). This shifts naive CD4+ T cell polarisation toward Foxp3+ Treg (+20–35% Treg frequency) at the expense of Th2 (+15–25% Th1/Th2 ratio), restoring peripheral tolerance mechanisms. Increased Treg-derived IL-10 suppresses mast cell and eosinophil activation. SCFA from spirulina polysaccharide gut fermentation (butyrate, propionate) promote colonic Treg expansion via HDAC inhibition, supporting mucosal tolerance and reducing food allergen translocation through improved tight junction barrier function (+15–25% TEER).
Eosinophil Recruitment Inhibition
NF-κB-driven eotaxin (CCL11) and RANTES (CCL5) expression in airway epithelial cells and fibroblasts reduced −20–35% by phycocyanin NF-κB inhibition, directly reducing eosinophil tissue accumulation. Circulating eosinophils −15–25% in atopic/asthmatic models; tissue eosinophilia (BAL eosinophil count) −20–30%. IL-5 reduction (−20–30%) decreases eosinophil bone marrow production and survival. Combined effect: reduced eosinophil-derived granule proteins (MBP, ECP) in tissues, protecting epithelial integrity from eosinophil cytotoxic damage.
Clinical Outcomes in Allergy
- Total serum IgE: −20–35% at 8–16 weeks
- Nasal symptom score (rhinitis): −30–45%
- Blood eosinophil count: −15–25%
- Skin prick test wheal diameter: −15–25%
- Serum IL-4: −25–40%
- SCORAD (atopic dermatitis): −20–35%
Dosing and Drug Interactions
Allergic rhinitis/atopic conditions: 3–5g daily for 8–16 weeks before and during allergen season. Antihistamines (cetirizine, loratadine): Complementary; spirulina reduces upstream IgE/Th2 drive while antihistamines block H1 receptor. Inhaled corticosteroids: Spirulina anti-inflammatory mechanisms may reduce ICS dose requirement; do not reduce prescribed medications without physician guidance. Immunotherapy (SCIT/SLIT): Spirulina Treg promotion may enhance tolerisation; no interaction reported. Summary: IgE −20–35%, histamine −30–45%, eosinophils −15–25%, Treg +20–35%, nasal symptoms −30–45%; dosing 3–5g for 8–16 weeks. NK concern: low.